Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series

Bethesda. http://seer.cancer.gov/csr/1975_2013/. SEER web site, 2016. Cardoso, 2017, 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3), Ann Oncol, 10.1093/annonc/mdx036 Cardoso, 2009, International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy, J Natl Cancer Inst, 101, 1174, 10.1093/jnci/djp235 Reinert, 2015, Optimal management of hormone receptor positive metastatic breast cancer in 2016, Ther Adv Med Oncol, 7, 304, 10.1177/1758834015608993 Martinello, 2016, New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer, Expet Opin Pharmacother, 17, 2179, 10.1080/14656566.2016.1236914 Finn, 2016, Palbociclib and Letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 Swain, 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N Engl J Med, 372, 724, 10.1056/NEJMoa1413513 Santa-Maria, 2016, Management of metastatic HER2-positive breast cancer: where are we and where do we go from here?, Oncology (Williston Park), 30, 148 Ahmed, 2015, HER2-directed therapy: current treatment options for HER2-positive breast cancer, Breast Canc, 22, 101, 10.1007/s12282-015-0587-x Clark, 1987, The clinical pharmacology of etoposide and teniposide, Clin Pharmacokinet, 12, 223, 10.2165/00003088-198712040-00001 Wozniak, 1983, DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity, Cancer Res, 43, 120 Kalwinsky, 1983, Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts, Cancer Res, 43, 1592 Ross, 1984, Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage, Cancer Res., 44, 5857 Sullivan, 1986, Proliferation dependence of topoisomerase II mediated drug action, Biochemistry, 25, 2248, 10.1021/bi00356a060 Carney, 1992, Oral etoposide in small cell lung cancer, Semin Oncol, 19, 40 Hainsworth, 1989, Chronic daily administration of oral etoposide–a phase I trial, J Clin Oncol, 7, 396, 10.1200/JCO.1989.7.3.396 Atienza, 1995, Phase II study of oral etoposide for patients with advanced breast cancer, Cancer, 76, 2485, 10.1002/1097-0142(19951215)76:12<2485::AID-CNCR2820761212>3.0.CO;2-J Bontenbal, 1995, Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer, Breast Canc Res Treat, 34, 185, 10.1007/BF00665790 Calvert, 1993, Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results, Cancer Treat Rev., 19, 27, 10.1016/0305-7372(93)90045-S Cavalli, 1981, Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer, Onkologie, 4, 80 Icli, 2005, Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group, Br J Canc, 92, 639, 10.1038/sj.bjc.6602388 Erkisi, 1997, Refractory breast cancer: a comparison of two different chemotherapy regimens, J Chemother, 9, 442 Fountzilas, 1993, Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines, Tumori, 79, 389, 10.1177/030089169307900603 Fried, 2005, Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study, J BUON, 10, 201 Palombo, 1994, Chronic oral etoposide in advanced breast cancer, Canc Chemother Pharmacol, 33, 527, 10.1007/BF00686513 Jagodic, 2001, Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients, Anti Canc Drugs, 12, 199, 10.1097/00001813-200103000-00004 Nesković-Konstantinović, 1996, Daily oral etoposide in metastatic breast cancer, Anti Canc Drugs, 7, 543, 10.1097/00001813-199607000-00009 Martín, 1994, Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer, J Clin Oncol, 12, 986, 10.1200/JCO.1994.12.5.986 Mutlu, 2015, Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer, J Cancer Res Ther, 11, 287, 10.4103/0973-1482.154008 Saphner, 2000, 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature, Am J Clin Oncol, 23, 258, 10.1097/00000421-200006000-00010 Pusztai, 1998, Daily oral etoposide in patients with heavily pretreated metastatic breast cancer, Am J Clin Oncol, 21, 442, 10.1097/00000421-199810000-00004 Yuan, 2012, Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy, Chin Med J (Engl), 125, 775 Yuan, 2015, Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study, Medicine (Baltim), 94, e774, 10.1097/MD.0000000000000774 Valabrega, 2015, A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients, Breast J, 21, 241, 10.1111/tbj.12398 Cortes, 2011, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study, Lancet, 377, 914, 10.1016/S0140-6736(11)60070-6 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Dzimitrowicz, 2016, T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab, J Clin Oncol, 34, 3511, 10.1200/JCO.2016.67.3624 Perez, 2015, Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial, Lancet Oncol, 16, 1556, 10.1016/S1470-2045(15)00332-0